O
ACHL

OrbiMed’s Achilles Therapeutics ACHL Stock Holding History

OrbiMed’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,463,251
Closed -$3.31K – 133
2022
Q3 		$3.31K Sell
1,463,251
-121,594
-8% -$344K 0.06% 112
2022
Q2 		$3.99K Hold
1,584,845
– – 0.07% 118
2022
Q1 		$4.66M Hold
1,584,845
– – 0.08% 123
2021
Q4 		$7.94M Hold
1,584,845
– – 0.1% 122
2021
Q3 		$12.3M Hold
1,584,845
– – 0.14% 117
2021
Q2 		$15.5M Hold
1,584,845
– – 0.16% 107
2021
Q1 		$26.2M Buy
+1,584,845
New +$26.2M 0.25% 86

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

OrbiMed's ACHL Position: Q4 2022 in Review

OrbiMed sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 1,463,251 shares — an estimated $3.31K sold.

OrbiMed first reported a position in ACHL in Q1 2021 and held it in 7 quarters. The position peaked at $26.2M in Q1 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

  • OrbiMed reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
  • OrbiMed sold 1,463,251 Achilles Therapeutics shares in Q4 2022, an estimated $3.31K.
  • OrbiMed first reported a position in Achilles Therapeutics in Q1 2021 and held it in 7 quarters.
  • OrbiMed's Achilles Therapeutics position peaked at $26.2M in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.